<p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 免費報告）- HC Wainwright 的研究分析師在 8 月 11 日星期一向投資者發佈的研究報告中提高了對 Corvus Pharmaceuticals 2025 年第三季度每股收益的預期。HC Wainwright 的分析師 S. Lee 現在預計該公司本季度每股收益為（$0.14），高於之前的預期（$0.15）。市場普遍預計 Corvus Pharmaceuticals 當前全年的每股收益為（$0.63）。HC Wainwright 還對 Corvus Pharmaceuticals 2025 年第四季度的每股收益預期為（$0.14），2025 財年的每股收益預期為（$0.51），2026 年第一季度的每股收益預期為（$0.12），2026 年第二季度的每股收益預期為（$0.12），2026 年第四季度的每股收益預期為（$0.13），2026 財年的每股收益預期為（$0.50）以及 2027 財年的每股收益預期為（$0.40）。</p>
<p>其他幾位股票研究分析師最近也對該公司發佈了報告。瑞穗證券在 5 月 20 日星期二對 Corvus Pharmaceuticals 設定了 11.00 美元的目標價，並給予該股票 “跑贏大盤” 的評級。Oppenheimer 在 5 月 9 日星期五重申了 “跑贏大盤” 的評級，並將 Corvus Pharmaceuticals 的目標價從 15.00 美元上調至 17.00 美元。最後，華爾街 Zen 在 8 月 9 日星期六將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。一位股票研究分析師給予該股票 “持有” 評級，四位分析師給予該股票 “買入” 評級。根據 MarketBeat 的數據，Corvus Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 15.00 美元。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 警報：</p>
<p><strong>查看我們關於 CRVS 的最新研究報告</strong></p>
<h2>Corvus Pharmaceuticals 股價上漲 11.1%</h2>
<p>Corvus Pharmaceuticals 的股票在星期四以 5.00 美元開盤。該股票的 50 日移動平均價格為 4.21 美元，200 日移動平均價格為 4.05 美元。該公司的市值為 3.7255 億美元，市盈率為 -4.95，貝塔值為 0.42。Corvus Pharmaceuticals 的一年低點為 2.54 美元，一年高點為 10.00 美元。</p>
<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近在 8 月 7 日星期四公佈了季度收益數據。該公司報告的每股收益（EPS）為（$0.10），超過了市場普遍預期的（$0.13）3 美分。</p>
<h2>Corvus Pharmaceuticals 的內部買賣</h2>
<p>在其他新聞中，董事 Peter A. Thompson 於 6 月 27 日星期五出售了 1,176,332 股該公司的股票。該股票以平均價格 4.16 美元出售，總交易額為 4,893,541.12 美元。出售完成後，該董事直接持有該公司 7,165,006 股股票，價值 29,806,424.96 美元。此交易代表其持股減少了 14.10%。該交易已在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。28.50% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金最近對 CRVS 的持倉進行了調整。Sowell Financial Services LLC 在第一季度以約 38,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。Virtus ETF Advisers LLC 在第四季度以約 47,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。新澤西州警察和消防員退休系統在第二季度以約 49,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。ProShare Advisors LLC 在第二季度以約 54,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。最後，Alpine Global Management LLC 在第四季度以約 62,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。機構投資者和對沖基金持有該公司 46.64% 的股票。</p>
<h2>Corvus Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫、過敏和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>TSX 風險投資交易所（前稱加拿大風險投資交易所）</li>
<li>數據中心為這三隻核能股票創造了牛市案例</li>
<li>製造業股票投資</li>
<li>特斯拉的旗幟剛剛斷裂：這對股票意味着什麼</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>三家公司將從特朗普的半導體關税中獲利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在您考慮投資 Corvus Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Corvus制藥

<p>HC Wainwright 將 Corvus Pharmaceuticals (NASDAQ:CRVS) 2025 年第三季度每股收益預期從（$0.15）上調至（$0.14）。全年共識預期為每股（$0.63）。其他分析師的目標價範圍在 $11.00 到 $17.00 之間，平均評級為 “適度買入”，共識目標價為 $15.00。Corvus Pharmaceuticals 的股票開盤價為 $5.00，市值為 3.7255 億美元。該公司上個季度報告的每股收益為（$0.10），超出預期。內部交易顯示董事持股減少了 14.10%</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 免費報告）- HC Wainwright 的研究分析師在 8 月 11 日星期一向投資者發佈的研究報告中提高了對 Corvus Pharmaceuticals 2025 年第三季度每股收益的預期。HC Wainwright 的分析師 S. Lee 現在預計該公司本季度每股收益為（$0.14），高於之前的預期（$0.15）。市場普遍預計 Corvus Pharmaceuticals 當前全年的每股收益為（$0.63）。HC Wainwright 還對 Corvus Pharmaceuticals 2025 年第四季度的每股收益預期為（$0.14），2025 財年的每股收益預期為（$0.51），2026 年第一季度的每股收益預期為（$0.12），2026 年第二季度的每股收益預期為（$0.12），2026 年第四季度的每股收益預期為（$0.13），2026 財年的每股收益預期為（$0.50）以及 2027 財年的每股收益預期為（$0.40）。</p>
</div><p>Several other equities research analysts also recently issued reports on the company. Mizuho set a $11.00 price objective on Corvus Pharmaceuticals and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $15.00.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師最近也對該公司發佈了報告。瑞穗證券在 5 月 20 日星期二對 Corvus Pharmaceuticals 設定了 11.00 美元的目標價，並給予該股票 “跑贏大盤” 的評級。Oppenheimer 在 5 月 9 日星期五重申了 “跑贏大盤” 的評級，並將 Corvus Pharmaceuticals 的目標價從 15.00 美元上調至 17.00 美元。最後，華爾街 Zen 在 8 月 9 日星期六將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。一位股票研究分析師給予該股票 “持有” 評級，四位分析師給予該股票 “買入” 評級。根據 MarketBeat 的數據，Corvus Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 15.00 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 警報：</p>
</div><p><strong>View Our Latest Research Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CRVS 的最新研究報告</strong></p>
</div><h2>Corvus Pharmaceuticals Trading Up 11.1%</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股價上漲 11.1%</h2>
</div><p>Shares of Corvus Pharmaceuticals stock opened at $5.00 on Thursday. The stock has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.05. The company has a market cap of $372.55 million, a P/E ratio of -4.95 and a beta of 0.42. Corvus Pharmaceuticals has a 1 year low of $2.54 and a 1 year high of $10.00.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals 的股票在星期四以 5.00 美元開盤。該股票的 50 日移動平均價格為 4.21 美元，200 日移動平均價格為 4.05 美元。該公司的市值為 3.7255 億美元，市盈率為 -4.95，貝塔值為 0.42。Corvus Pharmaceuticals 的一年低點為 2.54 美元，一年高點為 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近在 8 月 7 日星期四公佈了季度收益數據。該公司報告的每股收益（EPS）為（$0.10），超過了市場普遍預期的（$0.13）3 美分。</p>
</div><h2>Insider Buying and Selling at Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, Director Peter A. Thompson sold 1,176,332 shares of the firm's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the completion of the sale, the director directly owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. 28.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Peter A. Thompson 於 6 月 27 日星期五出售了 1,176,332 股該公司的股票。該股票以平均價格 4.16 美元出售，總交易額為 4,893,541.12 美元。出售完成後，該董事直接持有該公司 7,165,006 股股票，價值 29,806,424.96 美元。此交易代表其持股減少了 14.10%。該交易已在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。28.50% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in CRVS. Sowell Financial Services LLC acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $38,000. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter valued at about $47,000. Police &amp; Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $49,000. ProShare Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近對 CRVS 的持倉進行了調整。Sowell Financial Services LLC 在第一季度以約 38,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。Virtus ETF Advisers LLC 在第四季度以約 47,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。新澤西州警察和消防員退休系統在第二季度以約 49,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。ProShare Advisors LLC 在第二季度以約 54,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。最後，Alpine Global Management LLC 在第四季度以約 62,000 美元的價格收購了 Corvus Pharmaceuticals 的新股份。機構投資者和對沖基金持有該公司 46.64% 的股票。</p>
</div><h2>Corvus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫、過敏和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>Manufacturing Stocks Investing</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>TSX 風險投資交易所（前稱加拿大風險投資交易所）</li>
<li>數據中心為這三隻核能股票創造了牛市案例</li>
<li>製造業股票投資</li>
<li>特斯拉的旗幟剛剛斷裂：這對股票意味着什麼</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>三家公司將從特朗普的半導體關税中獲利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮投資 Corvus Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 Corvus Pharma 第三季度收益的預測是什麼？